Blood Test Detects Brain Tumors with 90% Accuracy

A revolutionary blood test could soon transform how doctors detect and monitor deadly brain tumors, offering hope to thousands facing one of cancer's most devastating forms.

Scientists at the University of Manchester have developed a simple blood test that identifies aggressive glioblastomas with over 90% accuracy. The test works by detecting two specific blood proteins that signal the presence of tumors, even as the disease evolves and changes.

Currently, patients experiencing persistent headaches often visit their GP six to eight times before getting an MRI scan for a potential brain tumor. By then, tumors may have grown significantly larger, making treatment more difficult and damaging more healthy brain tissue during surgery.

The new test could change that timeline dramatically. If a patient visits their doctor multiple times with headaches, a simple blood draw could indicate whether an MRI is necessary, catching tumors when they're smaller and more treatable.

Professor Petra Hamerlik, who lost her own father to glioblastoma, led the research team. She tested the blood markers on patients throughout their entire treatment journey, including surgery, radiotherapy, and chemotherapy. The results remained stable and reliable at every stage.

What makes this discovery particularly remarkable is how the test adapts to the tumor's behavior. When patients began treatment after surgery, the biomarkers changed accordingly. They rose as tumors grew back and fell when chemotherapy was working, giving doctors real-time feedback without invasive procedures.

Why This Inspires

This breakthrough represents more than just scientific progress. It's personal. Professor Hamerlik channeled her grief into action, determined that other families might catch this devastating disease earlier than her father did.

The test's simplicity makes it even more powerful. Hamerlik envisions a device similar to a COVID rapid test that could be available in GP offices within a decade, pending regulatory approval. No specialized equipment, no hospital visits, just a quick blood draw that could save lives.

The team has already launched clinical trials across six UK sites and four international locations. While glioblastoma treatments remain limited, having an accurate monitoring tool ready means doctors can act faster when new medicines become available.

Dr. Simon Newman from the Brain Tumour Charity called the research "a significant step" toward giving clinicians the tools they desperately need. Early detection doesn't just improve survival rates; it preserves quality of life by catching tumors before they cause irreversible brain damage.

The blood test also offers continuous monitoring without repeated MRI scans, reducing both healthcare costs and patient anxiety. Families will know sooner if treatments are working or if adjustments are needed, replacing uncertainty with actionable information.

For the thousands diagnosed with glioblastoma each year, this simple blood test represents something profound: the chance to catch their cancer early enough to fight back.